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PURPOSE 
We aimed to evaluate the role of fluorine-18 fluorodeoxy-
glucose positron emission tomography-computed tomogra-
phy (18F-FDG PET-CT) involving care-dose unenhanced CT to 
detect extranodal involvement in patients with non-Hodgkin 
and Hodgkin lymphoma.  
MATERIALS AND METHODS
Lymphoma patients (35 Hodgkin lymphoma, 75 non-Hod-
gkin lymphoma) who were referred for 18F-FDG PET-CT im-
aging, following a diagnostic contrast-enhanced CT (CE-CT) 
performed within the last month, were included in our study. 
A total of 129 PET-CT images, and all radiologic, clinical, and 
pathological records of these patients were retrospectively 
reviewed. 
RESULTS
In total, 137 hypermetabolic extranodal infiltration sites were 
detected by 18F-FDG PET-CT in 62 of 110 patients. There 
were no positive findings by CE-CT that reflected organ in-
volvement in 40 of 137 18F-FDG-positive sites. The κ statistics 
revealed fair agreement between PET-CT and CE-CT for the 
detection of extranodal involvement (κ=0.60). The organs 
showing a disagreement between the two modalities were 
the spleen, bone marrow, bone, and thyroid and prostate 
glands. In all lesions that were negative at CE-CT, there was 
a diffuse 18F-FDG uptake pattern in the PET-CT images. The 
frequency of extranodal involvement was 51% and 58% in 
Hodgkin and non-Hodgkin lymphoma patients, respectively. 
There was a high positive correlation between the maximum 
standardized uptake values of the highest 18F-FDG-accumu-
lating lymph nodes and extranodal sites (r=0.67) in patients 
with nodal and extranodal involvement. 
CONCLUSION
18F-FDG PET-CT is a more effective technique than CE-CT for 
the evaluation of extranodal involvement in Hodgkin and 
non-Hodgkin lymphoma patients. PET-CT has a significant ad-
vantage for the diagnosis of diffusely infiltrating organs with-
out mass lesions or contrast enhancement compared to CE-CT.
L ymphomas are common hematological malignancies that predom-inantly affect the lymph nodes. However, both non-Hodgkin lym-phoma (NHL) and Hodgkin lymphoma (HL) may affect any organ 
or tissue in the body. The lymphomatous infiltration of tissues other 
than the lymph nodes or lymphoid organs is described as extranodal 
lymphoma. The most common sites of lymphomatous infiltration are 
skin, stomach, spleen, Waldeyer’s ring, central nervous system, bone, 
and lungs. The distribution and prevalence of affected organs vary ac-
cording to the histological type and stage of the disease (1–4). 
The presence of extranodal involvement is very important for staging 
NHL and HL. In general, extranodal involvement is more common in 
NHL than in HL, while it is frequently observed in recurrent disease 
and immune deficiency-related lymphomas (2–4). Moreover, primary 
and secondary extranodal diseases have different prognostic implica-
tions. Lymphomas that initially appear to have the bulk of the disease 
at extranodal sites are described in primary extranodal lymphoma and 
categorized as stage I or II. In secondary extranodal lymphoma, there is 
secondary involvement of the extranodal sites from primary nodal dis-
ease, which is categorized as stage III or IV. Except for the thymus and 
spleen, extranodal infiltration also indicates stage IV disease in HL. All 
of these data demonstrate the vital importance of diagnosis of extran-
odal lymphoma when designing treatment protocols at primary staging 
or restaging (3–5).
Cross-sectional anatomical imaging techniques, particularly comput-
ed tomography (CT), have been the primary modality for the diagnosis, 
staging, restaging, and follow-up of patients with lymphoma. Howev-
er, these modalities have several limitations when detecting nodal or 
extranodal disease, because CT is based only on anatomical structural 
changes, such as the enlargement of lymph nodes or organs, presence 
of masses, and abnormal contrast enhancements. In NHL or HL, these 
structural abnormalities are detected in 60% to 90% of patients by CT 
(6–8). Normal-sized organs or nodes and diffuse lymphomatous infiltra-
tions without mass effects reduce the sensitivity of anatomical imaging 
modalities.
Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomogra-
phy-computed tomography (PET-CT) is a hybrid imaging technique that 
simultaneously provides functional and anatomical information. This 
provides a significant advantage for the evaluation of lymphoproliferative 
malignancies, particularly for the detection of lymphomatous involve-
ment in organs and nodes of normal size without any mass. Several stud-
ies suggest that the sensitivity and specificity of 18F-FDG PET-CT for the 
assessment of nodal and extranodal involvement were higher than those 
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of standard contrast-enhanced CT (CE-
CT) (3, 4, 7–11). These benefits make 
18F-FDG PET-CT the standard imaging 
technique for the initial staging, ther-
apy response evaluation and restaging 
of patients with lymphoma. 
The aim of this study was to evaluate 
the utility of 18F-FDG PET-CT involv-
ing care-dose unenhanced CT for the 
detection of extranodal involvement 
in patients with NHL and HL. The 
18F-FDG PET-CT results were retrospec-
tively compared with the diagnostic 
CE-CT data; follow-up results were 
used as a reference standard.
Materials and methods
Patients
From October 2011 to November 
2012, 110 lymphoma patients (41 fe-
males, 69 males; mean age, 43.9±21.4 
years) were included in this study. We 
evaluated those patients who had a di-
agnostic CE-CT evaluation within the 
previous month and were referred for 
18F-FDG PET-CT imaging. One hundred 
and twenty-nine PET-CT images, and 
all radiological, clinical, and patholog-
ical records of these 110 patients were 
retrospectively reviewed.
Thirty-five patients (13 females, 22 
males; mean age, 43.5±21.5 years) had 
histologically proven HL, while 75 (28 
females, 47 males; mean age, 43.9±21.4 
years) had NHL. The histological classi-
fications of the patients are presented in 
Table 1. Out of 129 18F-FDG PET-CT im-
ages, 52 were obtained for staging, 61 for 
therapy response evaluation, and 16 for 
restaging. PET-CT and CE-CT were per-
formed after at least two cycles of che-
motherapy, two weeks after the comple-
tion of chemotherapy or three months 
after the completion of radiotherapy to 
evaluate the therapeutic response. 
The clinical and laboratory records 
of the patients were reviewed retro-
spectively in accordance and with the 
local ethics guidelines, and written in-
formed consent was obtained from the 
subjects.  
Imaging
Patients were injected intravenous-
ly with 250–450 MBq of 18F-FDG at 
least six hours after the fasting period 
for 18F-FDG PET-CT imaging. Approxi-
mately one hour after injection (40–60 
min), PET-CT scanning was performed 
from the head to the proximal thigh 
using a clinical PET-CT system (Bi-
ograph high-definition 16-slice CT, 
Siemens Healthcare, Erlangen, Germa-
ny). CT scans were acquired using 80 
kV tube voltage, 120 mA tube current, 
0.6 s rotation time, 0.6 mm slice col-
limation, and kernel B31f for recon-
struction. PET imaging was performed 
at 1 mm/min in bed position, and a 
512×512 matrix and iterative recon-
struction methods were used for the re-
construction of the PET images (atten-
uation-weighted, three iterations and 
24 subsets, matrix size of 512, zoom of 
10 isotropic, and CT resolution of 0.24 
mm with 2 mm uniform resolution 
throughout the field of view).
PET and CT images were loaded on 
three-dimensional workstations for 
data analysis and visual evaluation. 
Attenuation-corrected and non-at-
tenuation corrected images, as well 
as maximum intensity projections of 
PET, CT, and fusion PET-CT images, 
were evaluated visually on three or-
thogonal planes (coronal, sagittal, and 
axial). For quantitative evaluations, 
image analysis software (Syngo® On-
cology Engine with TrueD™, Siemens 
Healthcare) was used. The 18F-FDG up-
take of the involved lymph nodes or 
tissues was quantified and identified 
as the maximum standardized uptake 
value (SUVmax) using the image analy-
sis software program and the follow-
ing formula: SUV=tissue radioactivity 
concentration (Bq/mL)/(injected dose 
[Bq]/body weight [g]). 
CE-CT was performed independent-
ly in different centers equipped with 
multislice helical CT scanners within 
the last month (mean, 11±9 days) be-
fore PET-CT imaging. 
All pathologic findings observed 
with 18F-FDG PET-CT were directly 
compared with CE-CT. Detection of 
changes in density or pathologic con-
trast enhancement by CT in extralym-
phatic tissues and increased uptake of 
18F-FDG at these mass lesions (n=97) 
were accepted as extranodal infiltra-
tions. In suspected lesions without 
typical CT findings indicating lym-
phomatous infiltration but with an in-
creased uptake of 18F-FDG (n=40), the 
presence of extranodal involvement 
was proved depending on the biopsy 
(n=25), magnetic resonance imaging 
(MRI) (n=3), or PET-CT data follow-
ing the treatment observation (n=12). 
While a bone marrow biopsy was ob-
tained during the staging of all cases, 
the biopsy results determined bone 
marrow infiltration for cases with dif-
fused intramedullary bone uptake at 
18F-FDG PET-CT. The criteria for bone 
marrow infiltration in 18F-FDG PET-
CT were focal areas of increased tracer 
uptake or a diffusely increased uptake 
in patients not treated with drugs af-
fecting the bone marrow. In cases with 
undetected lesions on the CE-CT and 
increased diffuse 18F-FDG uptake in 
Table 1. Histological classification and subtypes of the patients with Hodgkin and 
non-Hodgkin lymphoma 
Histopathology Subtypes Number of patients Female/Male
HL Nodular sclerosing 22 9/13
 Mixed cellularity 11 4/7
 Lymphocyte-rich 2 0/2
High-grade NHL Diffuse large B cell 48 18/30
 Peripheral T cell 3 0/3
 Burkitt lymphoma 2 2/0
 Anaplastic large cell 2 1/1
 Lymphoblastic 2 1/1
Low-grade NHL Follicular 7 1/6
 Marginal zone 4 2/2
 Mantle cell 3 1/2
 MALT 2 2/0
 Chronic lymphocytic leukemia 2 0/2
HL, Hodgkin lymphoma; MALT, mucosa associated lymphoid tissue, NHL, non-Hodgkin lymphoma.
PET-CT for extranodal staging of lymphoma • 187
the spleen on the PET-CT before treat-
ment, patients were accepted as splen-
ic infiltration cases if they were not 
treated with chemotherapy or colony 
stimulating factor drugs, SUV levels of 
the spleen was over the liver, or spleen 
activity decreased together with the 
other uptake regions on post-therapy 
PET-CT. The diagnosis was confirmed 
with tissue biopsies in cases with in-
creased 18F-FDG uptakes indicating 
lymphomatous infiltrations in the 
thyroid gland, prostate, and stomach. 
Statistical analysis
The agreement of PET-CT and CE-CT 
findings for extranodal lymphomatous 
involvement was assessed with the κ 
statistic. The agreements classified by 
the κ values were as follows: 0–0.20, 
very poor; 0.21–0.40, poor; 0.41–0.60, 
fair; 0.61–0.80, good; and 0.81–1.00, 
excellent. The Wilcoxon signed-rank 
test was used to compare the detect-
ability of the lesions between the PET-
CT and CE-CT. The correlations be-
tween the SUVmax of the lymph nodes 
and extranodal sites of the same pa-
tient and between patient groups were 
evaluated with Pearson’s correlation 
analysis. The student’s t test was used 
to evaluate the differences between the 
prevalence of extranodal involvement 
in different histological types and in 
the study group. Data were analyzed 
using the Statistical Package for the 
Social Sciences (SPSS) software (version 
15.0 for Windows; SPSS Inc., Chicago, 
Illinois, USA). A P value of <0.05 was 
accepted as statistically significant.
Results
Sixty-two of 110 patients (56%) 
with lymphoma who had undergone 
18F-FDG PET-CT imaging and CE-CT 
evaluation had one or more extranodal 
sites. All 137 of the hypermetabolic ex-
tranodal infiltration sites were detect-
ed by 18F-FDG PET-CT in these 62 pa-
tients. Positive findings reflected organ 
involvement, such as mass lesions or 
abnormal contrast enhancement, in 97 
of 137 hypermetabolic extranodal sites 
upon CE-CT. There was no organ in-
volvement found in 40/137 of the high 
18F-FDG accumulating extranodal sites 
with CE-CT. The extranodal infiltra-
tion sites of the patients, and 18F-FDG 
PET-CT and CE-CT findings based on 
the lesion are presented in Table 2. 
The κ statistics revealed fair agreement 
between PET-CT and CE-CT for the 
detection of extranodal involvement 
(κ=0.60). Disagreements were observed 
between the two modalities regarding 
the spleen, bone marrow, bone, and 
thyroid and prostate glands (Table 2). 
All of these lesions with negative CE-
CTs had diffuse 18F-FDG uptake pat-
terns in the PET-CT images.
The uptake regions were bone, bone 
marrow, spleen, liver, thyroid gland 
(Fig. 1), and prostate gland (Fig. 2), as 
detected by hypermetabolic involve-
ment with 18F-FDG PET-CT and then 
confirmed by biopsy, MRI, or follow-up 
results, with no detection of the lesion 
by CE-CT. There were diffused infiltra-
tions and diffuse 18F-FDG uptakes in all 
regions, except for the bone and liver.
On the patient-based evaluation, 24 
of 110 patients had CE-CT negativity 
and hypermetabolic foci or focus in the 
extranodal organs. Because there were 
other hypermetabolic extralymphatic 
regions involved in 18 of 24 patients, 
the 18F-FDG PET-CT data did not result 
in any change of the staging. However, 
in six cases, 18F-FDG PET-CT caused an 
upstaging of the disease and changes 
in management through the demon-
stration of extranodal organ involve-
ment that was undetected by CE-CT 
(Table 3). The percentages of patients 
downstaged and upstaged by PET-CT 
were 1.8% and 5.4%, respectively. The 
staging and post-therapeutic PET-CT 
findings of 24 patients with discordant 
18F-FDG PET-CT and CT results are pre-
sented in Table 3.
PET-CT resulted in a downstaging in 
two patients. There was extralymphat-
ic involvement in the esophagus of one 
patient, as demonstrated by CT, while 
the other had higher involvement. 
18F-FDG uptake was not observed other 
than in the lymph nodes upon PET-
CT in these cases; benign differences 
were confirmed by biopsy. No cases 
were reported as false positives based 
on PET-CT with the criteria we used, as 
explained in methods section.
Table 2. Number of patients with extranodal involvement detected by 18F-FDG PET-CT and 
CE-CT 
 High 18F-FDG activity  Positive CE-CT Negative CE-CT
Extranodal site NHL HL NHL HL NHL HL
Lung 2 6 2 6 0 0
Pleura 6 1 6 1 0 0
Spleen 19 7 5 6 14 1
Bone  10 2 7 2 3 0
Bone marrow 11 6 0 0 11 6
Thyroid gland 2 1 0 0 2 1
Peritoneal cavity 5 0 5 0 0 0
Adrenal glands 3 0 3 0 0 0
Kidneys 3 2 3 2 0 0
Testicle 1 0 1 0 0 0
Prostate 2 0 1 0 1 0
Brain 3 1 3 1 0 0
Liver 2 5 1 5 1 0
Pancreas 2 0 2 0 0 0
Naso- or oropharynx,  11 3 11 3 0 0 
tonsils 
Stomach 2 0 2 0 0 0
Thymus 4 0 4 0 0 0
Soft tissue and skin 12 3 12 3 0 0
CE-CT, contrast-enhanced computed tomography; 18F-FDG PET-CT, fluorine-18 fluorodeoxyglucose 
positron emission tomography-computed tomography; HL, Hodgkin lymphoma; NHL, non-Hodgkin 
lymphoma. 
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The relationship between the his-
tological type of lymphoma and the 
prevalence and locations of extranod-
al sites are presented in Tables 2 and 
4. The frequency of extranodal in-
volvement was 51% (18/35) and 58% 
(44/75) in patients with HL and NHL, 
respectively. The most affected sites 
were the lungs, bone, bone marrow, 
spleen, and liver in HL, whereas the 
most affected sites in NHL were the 
spleen, bone, bone marrow, Waldey-
er’s ring, and soft tissue. Lung and liver 
involvement was significantly higher 
in HL than in NHL patients. However, 
the rates of lymphomatous infiltration 
of the bone, adrenal glands, testicle, 
prostate, pancreas, soft tissue, Wald-
eyer’s ring, stomach, and thymus were 
significantly higher in NHL than in HL 
patients (Table 2). There was no signif-
icant correlation between histological 
type, grade, 18F-FDG affinity (SUV) of 
the tumor and the detection of extran-
odal sites with 18F-FDG PET-CT or CE-
CT in the study group (P < 0.05). 
In this study group, 29 patients had 
involvement in the cervical, thorac-
ic, and abdominopelvic lymph nodes 
(three sites), while 27 patients had one 
or two lymphatic regions involved. 
Six patients had no lymph nodes in-
volved. The SUVmax values of lymph 
nodes and extranodal sites were exam-
ined in patients having lymph node 
and extranodal involvements. 
The mean SUVmax value was 
23.3±13.2 for lymph nodes, which 
had the highest SUVmax in staging and 
restaging PET-CT scans, whereas the 
value was 7.4±2.8 in the post-therapy 
scans. The mean SUVmax for the extran-
odal infiltration sites was 20.6±14.2 
in the staging/restaging PET-CT stud-
ies and 6.3±3.2 in the post-therapy 
PET-CT scans. There is a high positive 
correlation between the SUVmax val-
ues of the highest 18F-FDG accumulat-
ing lymph nodes and extranodal sites 
(r=0.67) in patients with nodal and ex-
tranodal involvement. 
Table 3. 18F-FDG PET-CT findings of the patients’ with discordant PET and CT results during staging and after treatment 
Histological Extranodal involvement sites  Method of diagnostic Post-therapeutic
type detected by 18F-FDG PET-CT confirmation 18F-FDG PET-CT results
Patients with disease upstaged by 18F-FDG PET-CT 
NHL Bone, bone marrow* Biopsy (bone marrow) Complete metabolic response
NHL Bone (clivus)*, spleen* MRI Complete metabolic response
NHL Prostate* Biopsy -
NHL Spleen*, bone marrow* Biopsy (bone marrow) Complete metabolic, partial anatomic response
NHL Spleen*, bone marrow* Splenectomy Progressive disease
NHL Thyroid*, spleen*, bone marrow* Biopsy (thyroid, bone marrow) Complete metabolic response
Patients with disease stage unchanged by 18F-FDG PET-CT 
HL Bone, bone marrow*, spleen  Complete metabolic, partial anatomic response
HL Bone marrow*, kidney, liver, spleen, thyroid*  Biopsy (bone marrow) Complete metabolic, partial anatomic response
HL Bone marrow*, kidney, lung, spleen* Biopsy (bone marrow) -
HL Bone marrow*, lung, pleura  Progressive disease
HL Bone marrow*, lung, spleen  Biopsy (bone marrow) -
HL Bone marrow*, spleen  Biopsy (bone marrow) -
NHL Bone (scapula)*, peritoneum, spleen* MRI -
NHL Adrenal gland, bone marrow*, lung,  Biopsy (Waldeyer’s ring) Progressive disease 
 peritoneum, spleen*, Waldeyer’s ring 
NHL Bone, bone marrow*, liver*, spleen MRI -
NHL Bone, bone marrow*, lung, pleura,  Biopsy (bone marrow) Complete metabolic, partial anatomic response 
 soft tissue, spleen* 
NHL Bone, bone marrow*, lung, spleen*  Complete metabolic and anatomic response
NHL Bone marrow*, liver, lung, spleen* - Complete metabolic, partial anatomic response
NHL Bone marrow*, liver, spleen*  Complete metabolic and anatomic response
NHL Bone marrow*, lung, spleen* Biopsy (bone marrow) Complete metabolic, partial anatomic response
NHL Diaphragm, peritoneum, pleura, spleen*, thyroid* Biopsy (thyroid) Complete metabolic, partial anatomic response
NHL Nasopharynx, pancreas, spleen*  - Partial metabolic and anatomic response
NHL Spleen*, stomach Biopsy (bone marrow, stomach) Complete metabolic and anatomic response
*18F-FDG(+)/CT(-) extranodal foci.
18F-FDG PET-CT, fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography; HL, Hodgkin lymphoma; MRI, magnetic resonance 
imaging; NHL, non-Hodgkin lymphoma.
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Discussion
18F-FDG PET-CT has been routinely 
used for staging, restaging, and ther-
apy monitoring in patients with HL 
and high-grade NHL. This is a com-
bined technique that presents the 
functional and anatomical data at the 
same imaging session. Various groups 
have used care-dose CT without the 
injection of intravenous iodinated 
contrast agent for attenuation, cor-
rection, or anatomical correlation. 
Previous studies revealed that 18F-FDG 
PET-CT has a higher sensitivity and 
specificity than CE-CT in the eval-
uation of HL and high-grade NHL 
(3, 4, 7–11). Moreover, several stud-
ies have suggested that PET imaging 
with care-dose unenhanced CT alone 
might be sufficient for staging, ther-
apy monitoring, or follow-up in pa-
tients with HL and aggressive NHL, 
except in special cases (7, 12). In this 
study, we aimed to evaluate the utility 
of 18F-FDG PET with care-dose unen-
hanced CT to investigate the presence 
of extranodal spreading in NHL and 
HL patients.
Schaefer et al. (7) demonstrated that 
18F-FDG PET-CT with unenhanced CT 
has a higher sensitivity and specifici-
ty (100% and 90%, respectively) than 
CE-CT (88% and 50%, respectively) 
for the detection of extralymphatic 
involvement in patients with HL and 
high-grade NHL. Their results revealed 
that PET-CT is a more effective tech-
nique for the management of patients 
and might be sufficient, especially to 
exclude persistent or recurrent nod-
al-extranodal disease. In the current 
study, 137 hypermetabolic extran-
odal involvement sites, as confirmed 
by biopsy, radiological findings, or 
follow-up results, were detected with 
18F-FDG PET-CT in 62 patients with 
HL and NHL. Ninety-seven of these 
18F-FDG-positive extranodal sites 
(70%) had positive findings for organ 
involvement on CE-CT. However, 
there was no extranodal involvement 
in 40 of 137 hypermetabolic foci (30%) 
with high-dose CE-CT. Nearly, all of 
these CT-negative involvement sites 
had diffuse and nonfocal 18F-FDG up-
take patterns on PET-CT images, and 
the type of lymphomatous involve-
ment was diffusely infiltrative with-
out mass lesions. Contrast-enhanced 
CT-negative organs demonstrating the 
involvement of diffusely accumulating 
18F-FDG were the spleen, bone marrow, 
thyroid gland, and prostate. These re-
sults suggested that the involved organ 
and infiltration pattern were the most 
prominent factors for the detection of 
extranodal involvement with CE-CT. 
The results of this study noted that 
18F-FDG PET-CT has a significant ad-
vantage for the diagnosis of diffusely 
infiltrating organ involvements and is 
superior to CE-CT. 
Several studies in the literature re-
ported that 18F-FDG PET-CT was an 
effective and reliable method to eval-
uate lymphomas in the pre-treatment 
and post-treatment periods; it was 
shown to be superior to CT for the ob-
servation of normal-sized but involved 
Figure 1. a–d. Unenhanced CT (a), PET-CT (b), PET (c), and maximum intensity projection 
(MIP) (d) images for staging a 63-year-old patient with marginal zone non-Hodgkin lymphoma. 
There is diffuse 18F-FDG uptake in the left lobe of the thyroid gland without CT findings. High 
18F-FDG accumulation is also observed in spleen, bone marrow, Waldeyer’s ring, submandibular 
glands, and cervical lymph nodes on the MIP image (d). Biopsy showed lymphomatous 
involvement in the bone marrow, thyroid gland, and Waldeyer’s ring.
a
c
b
d
Table 4. Prevalence of extranodal involvement in different histological types and histological grades of lymphoma 
Histological Extranodal involvement   Extranodal involvement
type n/N (%)  Histological subtype/grade n/N (%) 
HL 18/35 (51)  Nodular sclerosing 10/22 (45.4) 
   Mixed cellularity 8/11 (72.7) 
   Lymphocyte-rich 0/2 (0) 
NHL 44/75 (58)  High-grade 31/57 (54.3) 
   Low-grade 13/18 (72) 
HD, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.
190 • March–April 2014 • Diagnostic and Interventional Radiology Ömür et al.
lymph nodes and diffusely infiltrated 
sites, such as the spleen or bone mar-
row (7, 9, 11–18). The role of PET-CT 
for splenic involvement in patients 
with lymphoma was evaluated by dif-
ferent studies. The results showed that 
the initial staging of splenic lympho-
matous involvement, sensitivity and 
specificity of PET-CT were higher than 
those of the other diagnostic modali-
ties alone (17, 18). PET-CT was also a 
highly sensitive and specific method 
for diagnosing bone marrow involve-
ment in lymphomas (15, 16). Howev-
er, its reliability differed depending on 
the histological type of the lymphoma, 
and a bone marrow biopsy is still need-
ed (12, 16). In this study, the thyroid 
gland and prostate were the other or-
gans with a diffuse infiltrative involve-
ment and diffuse uptake of 18F-FDG. 
Tissue biopsies were performed for a 
definitive diagnosis in these patients, 
and lymphomatous involvement was 
confirmed. Our results demonstrat-
ed that if there was any diffusely in-
creased 18F-FDG uptake in any organ, it 
must be evaluated for the presence of 
lymphomatous involvement by MRI, 
biopsy or follow-up studies.
The major limitations of 18F-FDG PET-
CT are its physiological uptake sites; 
among the common causes of false 
positive uptakes are infection, inflam-
mation, and benign lesions. In such 
situations, the CT characteristics of the 
lesions must be examined. The urinary 
system, brain, stomach, and small and 
large bowel are physiological uptake 
or clearance sites for 18F-FDG. In this 
study, all the patients diagnosed with 
lymphomatous involvement at such 
organs had positive findings on CE-CT 
or unenhanced CTs, while infiltration 
of the lymphoma was confirmed by 
histological evaluation. There were no 
false positive results from the 18F-FDG 
PET-CT. These results suggest that high 
18F-FDG accumulations on the sites of 
the physiological 18F-FDG distribution 
must be confirmed by anatomical im-
aging modalities, endoscopic studies 
and biopsies for a definitive diagno-
sis. Some studies have also reported 
that structural CT abnormalities and 
uptake intensities can improve the 
reliability of 18F-FDG PET-CT for the 
differentiation of lymphomatous in-
filtration from physiological tracer ac-
tivity, but the uptake pattern has not 
been found to be a reliable marker (3, 
4, 8, 19–22). The Waldeyer’s ring and 
lungs are also sites that have relative-
ly high false positive results due to 
infectious or inflammatory reasons 
(23). Therefore, the CT characteristics, 
structural abnormalities, intensity and 
pattern of the 18F-FDG uptake must be 
carefully evaluated. The recognition 
of abnormal findings at the Waldey-
er’s ring is important in making an 
accurate decision for the pathologic 
assessments. A detailed clinical histo-
ry, such as whether PET-CT is a pre-
treatment or post-treatment, the time 
after the chemotherapy, and the treat-
ments received, should be taken into 
consideration during the evaluation of 
PET-CT. PET-CT was obtained after the 
treatment, and all the other lymphat-
ic-extralymphatic regions responded 
well to treatment. New 18F-FDG up-
take regions in the lung or oropharynx 
should be evaluated depending on the 
infection. In this study, no false posi-
tive results were detected in the lung 
or oropharyngeal regions upon PET-
CT evaluations, based on the applied 
criteria. 
The 18F-FDG affinity of a tumor is 
one of the major decisive factors in 
the detection of pathologies by PET-
CT. If structural abnormalities are not 
carefully examined, infiltrated lymph 
nodes or organs may be overlooked in 
low 18F-FDG-avid tumors, such as low-
grade NHLs. In this study, there was 
no significant correlation between the 
histological type or grade of lympho-
ma and the detection of extranodal 
involvement with 18F-FDG PET-CT or 
CE-CT. In low 18F-FDG-avid tumors, 
as in low-grade NHLs, lower detection 
rates were expected more than in high-
grade NHLs. However, the detected le-
sion rates in our low-grade NHL cases 
were close to the high-grade NHL cas-
es. This could have resulted from the 
inclusion of patients in advanced stag-
es of the disease. These patients were 
referred to our clinic for PET-CT im-
aging to restage the disease, including 
relapse findings, by CT.
In the current study, the frequency 
of extranodal involvement was 51% 
and 58% in patients with HL and NHL, 
respectively. The most frequent extra- 
nodal infiltrations were detected in the 
lung, bone marrow, spleen, and liver in 
Figure 2. a–d. Unenhanced CT (a), PET-CT (b), PET (c), and MIP (d) images for staging a 
39-year-old patient with diffuse large B cell lymphoma. High 18F-FDG uptake in the left part 
of the prostate gland is observed without CT findings. The patient also has conglomerated 
hypermetabolic lymph nodes in the cervical, thoracal, and abdominal regions, as well as liver, 
bone, and spleen involvement.
a
c
b
d
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patients with HL, while the most com-
mon infiltrations in NHL patients were 
in the spleen, bone marrow, Waldey-
er’s ring, and soft tissue. In the litera-
ture, extranodal involvement has been 
reported in 25% to 50% of NHL and 
in 5% to 20% of HL patients (1–7). In 
our group, the frequency of extranodal 
involvement was higher than that re-
ported in other series. There were some 
differences in the distribution of the af-
fected sites. While the frequency of liver 
and lung involvement has been shown 
to be quite low in the literature, our re-
sults revealed that there was a higher 
lymphomatous infiltration in HL cases 
than in NHL cases in these organs (3, 
4, 8). Differences in geographical or ge-
netic features, patient selection criteria 
for referring PET-CT imaging, stage or 
aggressiveness of the tumor, and a rel-
atively higher number of patients with 
secondary or recurrent disease might 
be responsible for this outcome. We 
obtained similar results regarding the 
frequency of extranodal uptake and the 
affected organs in NHL cases (3, 4, 8).
The SUV has been widely used for 
the semiquantitative measurement of 
normalized tissue radioactivity con-
centrations in PET-CT studies. This pa-
rameter is one of the major advantages 
of PET-CT especially in the follow-up 
of patients with 18F-FDG-avid tumors 
(24, 25). The mean or maximum SUV 
of all voxels within the region of inter-
est (SUVmean and SUVmax, respectively) 
has been used for the measurement 
of the cellular metabolism of a tumor 
with PET-CT. For the treatment re-
sponse, the SUVmax value was usually 
preferred because it is independent 
from the defined region of interest (24, 
25). An early treatment response, even 
before anatomical changes could be 
visualized, can also be evaluated with 
SUVmax (25, 26). Oh et al. (26) report-
ed that the SUVmax is an independent 
prognostic factor in primary extran-
odal diffuse large B cell lymphomas. 
They examined cutoff values of the 
SUVmax, mean tumor diameters and 
the relation between these parame-
ters and clinical outcomes in patients 
with diffuse large B cell lymphomas 
presenting in extranodal organs, lack-
ing in or demonstrating only minor 
lymph node involvement. Therefore, 
no possible relationship between the 
SUVmax of lymph nodes and the in-
volved organs could be evaluated (26). 
To our knowledge, no previous study 
has examined the possibility of a re-
lationship between the SUVmax of the 
involved lymph node, and the ex-
tranodal organs in the same patient 
with lymphoma. In this study, we de-
tected a high positive correlation be-
tween the SUVmax values of the highest 
18F-FDG-accumulating lymph nodes 
and extranodal sites. These data may 
indicate that the highest SUVmax of the 
nodal sites can help in the differential 
diagnosis of organ infiltrations over 
other 18F-FDG-avid benign conditions, 
such as inflammation or infection, es-
pecially in patients with high 18F-FDG 
accumulation in extranodal sites with-
out mass lesions.
Our results demonstrate that 18F-FDG 
PET-care-dose unenhanced CT is a 
more sensitive imaging modality than 
CE-CT alone for the evaluation of the 
extranodal involvement of patients 
with NHL and HL. This modality has 
substantial superiority to CE-CT in the 
diagnosis of diffusely infiltrated organs 
without mass lesion or contrast en-
hancement, such as the spleen, bone 
marrow, thyroid gland, and prostate 
gland. However, accurate criteria must 
be used for the evaluation of 18F-FDG 
PET-CT, and structural abnormalities 
must be examined carefully to manage 
patients accurately.
In conclusion, in lymphoma pa-
tients with nodal involvement and 
suspicious 18F-FDG PET-CT findings for 
extranodal infiltration, SUVmax of ex-
tralymphatic organs that is close to the 
SUVmax of maximum 
18F-FDG-accumu-
lating lymph nodes can be considered 
as lenfomatous infiltration. 
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